High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis
- PMID: 16784992
- DOI: 10.1016/j.humpath.2006.02.017
High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis
Abstract
Tissue inhibitors of metalloproteinases (TIMPs) play key roles in maintaining homeostasis of the extracellular matrix by controlling matrix metalloproteinases (MMPs). In addition to their role in regulating MMPs, TIMPs have also been shown to have pluripotential effects on cell growth, apoptosis, and differentiation. The aim of this study was to evaluate TIMP-2 level in serous ovarian tumor tissues and to understand further the role of TIMP-2 protein in ovarian tumorigenesis. The expression of TIMP-2 was assessed by immunohistochemistry in a total of 57 ovarian specimens, including 5 normal ovaries, 12 benign serous cystadenomas, 20 serous borderline tumors, and 20 serous carcinomas. In addition, we transfected a TIMP-2 plasmid into the gynecologic cancer cell lines SKOV-3, 2774, and HeLa and then assayed cell growth, apoptosis, and MMP-2 activation. We found that TIMP-2 immunostaining was significantly more frequent in serous carcinomas, mainly in tumor epithelium, compared with cells of the other tissues studied. Tissue inhibitor of metalloproteinase-2 overexpression in ovarian cancer cells did not mediate proapoptosis, inhibited cisplatin-induced apoptosis, and induced MMP-2 expression. These findings suggest that TIMP-2 may function to favor tumor growth in serous ovarian tumorigenesis. Additional research is now needed to elucidate further the role of TIMP-2 in the biologic behavior of ovarian serous tumors.
Similar articles
-
Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.Int J Oncol. 2008 Dec;33(6):1239-46. Int J Oncol. 2008. PMID: 19020757
-
[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].Ai Zheng. 2004 Oct;23(10):1194-8. Ai Zheng. 2004. PMID: 15473934 Chinese.
-
Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.Gynecol Oncol. 2000 Jun;77(3):369-76. doi: 10.1006/gyno.2000.5806. Gynecol Oncol. 2000. PMID: 10831344
-
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.Am J Obstet Gynecol. 2004 Sep;191(3):718-32. doi: 10.1016/j.ajog.2004.02.067. Am J Obstet Gynecol. 2004. PMID: 15467531 Review.
-
[New concepts of pathology in serious borderline tumor in ovarian neoplasm].Zhonghua Fu Chan Ke Za Zhi. 1998 Mar;33(3):182-3. Zhonghua Fu Chan Ke Za Zhi. 1998. PMID: 10682490 Review. Chinese. No abstract available.
Cited by
-
Effects of an Engineered Anti-HER2 Antibody chA21 on Invasion of Human Ovarian Carcinoma Cell In Vitro.Chin J Cancer Res. 2011 Jun;23(2):147-52. doi: 10.1007/s11670-011-0147-7. Chin J Cancer Res. 2011. PMID: 23482689 Free PMC article.
-
Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.J Histochem Cytochem. 2012 Jul;60(7):491-501. doi: 10.1369/0022155412446978. Epub 2012 Apr 17. J Histochem Cytochem. 2012. PMID: 22511598 Free PMC article.
-
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.Cytoskeleton (Hoboken). 2010 Aug;67(8):535-44. doi: 10.1002/cm.20465. Cytoskeleton (Hoboken). 2010. PMID: 20607860 Free PMC article.
-
Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.Oncotarget. 2016 Dec 6;7(49):81026-81048. doi: 10.18632/oncotarget.13186. Oncotarget. 2016. PMID: 27835587 Free PMC article.
-
Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.Oncol Rep. 2012 Apr;27(4):1049-57. doi: 10.3892/or.2011.1608. Epub 2011 Dec 22. Oncol Rep. 2012. PMID: 22200690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous